Looking Into Syros Pharmaceuticals's Return On Capital Employed
During Q4, Syros Pharmaceuticals's (NASDAQ:SYRS) reported sales totaled $5.70 million. Despite a 53.81% in earnings, the company posted a loss of $29.22 million. In Q3, Syros Pharmaceuticals brought in $3.83 million in sales but lost $19.00 million in earnings.
Why ROCE Is Significant
Changes in earnings and sales indicate shifts in Syros Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Syros Pharmaceuticals posted an ROCE of -0.32%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Syros Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.
For Syros Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.
Q4 Earnings Insight
Syros Pharmaceuticals reported Q4 earnings per share at $-0.62/share, which did not meet analyst predictions of $-0.5/share.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
